The ELAVL1 Knockout HEK293T Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population for gene disruption of ELAVL1, encoding the RNA-binding protein HuR. This heterogeneous pool enables immediate loss-of-function studies without clonal isolation, suitable for high-throughput screening and pooled functional assays. The platform leverages the highly transfectable HEK293T background for post-transcriptional research.
HEK293T cells, immortalized human embryonic kidney expressing adenoviral E1A/E1B and SV40 large T antigen, are prized for exceptional transfectability and protein expression. They are widely used for recombinant production, viral packaging, and genomic manipulation. This epithelial host offers a simplified system to investigate mRNA stability and signaling without tissue-specific variability, making it an ideal background for ELAVL1 knockout comparisons.
ELAVL1 product HuR stabilizes ARE-containing mRNAs upon activation by kinases p38 MAPK, AMPK, PKC, and ERK in response to stress and cytokines IL-1?? and TNF??. Cytoplasmic HuR binds and protects transcripts encoding proliferation and survival factors such as cyclin D1, Bcl-2, Mcl-1, VEGF, and c-Myc, as well as inflammatory mediators TNF?? and COX-2. HuR interplay with decay factors TTP and AUF1 and nuclear transporters CRM1 and importin-?? positions it as a key post-transcriptional integrator of stress signaling and growth pathways.
Knocking out ELAVL1 in HEK293T abrogates HuR-directed mRNA stabilization, reducing target protein expression and impairing proliferation, survival, and inflammatory responses. This polyclonal knockout population facilitates dissection of HuR-dependent pathways in an epithelial model, avoiding specialized cell-type confounders. It supports investigations into how stress kinases converge on HuR and enables analysis of editing heterogeneity on functional outcomes.
Applications include mRNA half-life measurement, RNA immunoprecipitation, luciferase reporter assays, and Western blotting. Ideal for target identification, HuR inhibitor screening, and senescence research. For further information, contact Ascent Research.
